2-Mar-2026
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Tue, 3-Mar 8:21 AM ET)
Cantor Fitzgerald Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)
TipRanks (Mon, 2-Mar 10:36 AM ET)
H.C. Wainwright Remains a Hold on BioMarin Pharmaceutical (BMRN)
TipRanks (Mon, 2-Mar 6:55 AM ET)
PRNewswire (Fri, 27-Feb 8:00 PM ET)
TipRanks (Thu, 26-Feb 8:50 AM ET)
TipRanks (Thu, 26-Feb 4:50 AM ET)
BioMarin to Participate in Four Upcoming Investor Conferences in March
PRNewswire (Tue, 24-Feb 9:01 AM ET)
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
PRNewswire (Mon, 23-Feb 4:05 PM ET)
PRNewswire (Wed, 18-Feb 5:31 PM ET)
PRNewswire (Tue, 17-Feb 9:00 AM ET)
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Biomarin Pharmaceutical trades on the NASDAQ stock market under the symbol BMRN.
As of March 2, 2026, BMRN stock price declined to $59.74 with 1,843,555 million shares trading.
BMRN has a beta of 0.64, meaning it tends to be less sensitive to market movements. BMRN has a correlation of 0.11 to the broad based SPY ETF.
BMRN has a market cap of $11.48 billion. This is considered a Large Cap stock.
Last quarter Biomarin Pharmaceutical reported $875 million in Revenue and $.46 earnings per share. This beat revenue expectation by $42 million and exceeded earnings estimates by $.10.
In the last 3 years, BMRN traded as high as $101.48 and as low as $50.76.
The top ETF exchange traded funds that BMRN belongs to (by Net Assets): IJH, VTI, VB, VBK, VXF.
BMRN has underperformed the market in the last year with a price return of -16.0% while the SPY ETF gained +16.7%. However, in the short term, BMRN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +10.9% vs +1.0% return in SPY. But in the last 2 weeks, BMRN shares have been beat by the market, returning -0.2% compared to an SPY return of +0.7%.
BMRN support price is $60.36 and resistance is $63.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMRN shares will trade within this expected range on the day.
